Genetic Engineering Market

The global Genetic Engineering Market is valued at USD 1.33 Billion in 2023 and is projected to reach a value of USD 6.71 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 19.7% between 2024 and 2032. The global market is driven by rising demand for genetically modified crops, advancements in CRISPR technology, increasing funding for biotechnology research, growing applications in pharmaceuticals & agriculture, and the need for personalized medicine.

Key Highlights

• North America dominated the market in 2023, with 40.2% market share, driven by substantial investments in genetic technologies, the growing popularity of stem cell therapies, and a favorable regulatory environment
• In 2023, the Genetic Markers segment dominated the market with a 61.5% share due to its crucial role in identifying genetic variations for disease diagnosis, personalized medicine, and targeted therapies
• Based on Devices, the PCR segment dominated the market in 2023, with 53.2% of the market share, driven by its critical role in amplifying DNA sequences for genetic analysis and research
• The development and refinement of genome editing tools, particularly CRISPR-Cas9, have revolutionized the Genetic Engineering landscape. Newer variants, such as base editing and prime editing, offer even more precise genetic modifications with reduced off-target effects

Product Overview

Based on Product, the global market is segmented into Biochemical and Genetic Markers. In 2023, the Genetic Markers segment dominated the global market with 61.5% of revenue share.

The Genetic Markers segment is a key component of the global market, holding a significant share due to its importance in identifying specific genes or DNA sequences associated with particular traits, diseases, or responses to treatments. Genetic markers like Single Nucleotide Polymorphisms (SNPs) and microsatellites, are crucial tools in research, diagnostics, & personalized medicine, enabling precise genetic analysis and targeted therapies. They are widely used in understanding the genetic basis of diseases, predicting disease risk, and developing gene-based treatments.

For example, BRCA1 & BRCA2 are genetic markers used to identify the risk of breast and ovarian cancers. The growing focus on genomics & precision medicine, combined with advancements in next-generation sequencing (NGS) & bioinformatics, drives the demand for genetic markers. The integration of genetic markers in drug development and clinical trials further strengthens their role in the expanding Genetic Engineering market.

Regional Overview

In 2023, North America dominated the global market with a revenue share of 40.2%. This is driven by the rising popularity of stem cell therapies. The United States, in particular, is a major contributor due to substantial investments in genetic technologies. This growing demand is set to further solidify North America's leadership in the Genetic Engineering sector. The increased pharmaceutical investment in gene editing companies and the presence of prominent biotechnology & pharmaceutical firms, along with academic and research institutions, significantly fuel the regional market growth. The region benefits from a supportive regulatory environment that fosters research & innovation in Genetic Engineering. Enhanced investments in precision medicine, gene therapies, & agricultural biotechnology further drive the market forward.

On the other hand, high costs associated with gene therapies and genetic testing, along with concerns about data privacy and ethical issues, may challenge widespread adoption and constrain the regional market growth.

Asia Pacific is emerging as the fastest-growing region in the global market, driven by rapid advancements in biotechnology & Genetic Engineering across countries such as China, Japan, India, and South Korea. Government initiatives supporting biotechnology R&D, alongside a strong focus on precision medicine and genomics, are further accelerating the market growth. China leads the region with its significant market share, strengthened by government support for genomic research and the presence of major players like Hebei Senlang Biotechnology.

Key Trends

1. CRISPR-Cas9 Advancements: Growing adoption of CRISPR-Cas9 and other gene-editing tools for precision medicine and agriculture, enhancing efficiency and reducing costs.
2. Rise of Gene Therapy: Increasing focus on gene therapy for treating genetic disorders and chronic diseases, driving R&D investments and clinical trials.
3. Synthetic Biology Growth: Expansion of synthetic biology applications, including biofuel production, bioplastics, and bio-based chemicals, fostering sustainable innovations.
4. Pharmaceutical Biotechnology Integration: Growing collaboration between biotech and pharmaceutical companies for drug discovery, personalized medicine, and immunotherapy development.
5. Regulatory Evolution: Evolving regulatory frameworks across regions to accommodate Genetic Engineering advancements, balancing innovation with ethical and safety considerations.
6. Expansion in Agriculture: Increasing use of genetically modified organisms (GMOs) to enhance crop yield, pest resistance, and nutrient profile, driving agricultural biotechnology growth.

Market Dynamics

Genetic Engineering Overview

Genetic Engineering, also known as gene editing, involves laboratory techniques to modify the DNA of organisms. This process includes altering, adding, or deleting genes to achieve specific traits. Genetic Engineering can involve changing a single base pair in the DNA sequence, removing a section of DNA, or introducing new DNA segments. This technology is used across various fields, including cancer therapy, agriculture, and environmental management. Gene therapy & Genetic Engineering are closely related and share the goal of modifying genetic material to improve or cure diseases. Key techniques in Genetic Engineering include Recombinant DNA Technology, CRISPR-Cas9 gene editing, PCR (Polymerase Chain Reaction), Gene Synthesis, and Gene Silencing. These methods are crucial in driving growth in the Genetic Engineering Market.

Adoption of GMOs in Agriculture

Farmers' adoption of genetically modified organisms (GMOs) has been steadily increasing due to their ability to meet specific agricultural needs. GMOs are engineered to have traits like pest resistance, herbicide tolerance, improved nutritional content, and longer shelf life. These modifications help boost crop yields, reduce pesticide use, and address food security issues. As the global population grows, the demand for efficient & resilient crops is rising. Research using advanced gene editing tools is leading to the development of new crop varieties, making agriculture a key driver of growth in the global market.

Role of Gene Editing Technologies

Advances in gene editing technologies, especially CRISPR-Cas9, have significantly impacted the global market. CRISPR-Cas9 offers a highly efficient and precise method for modifying DNA, allowing scientists to make targeted changes with ease. Its simplicity and versatility have accelerated Genetic Engineering research & expanded its applications. For instance, in 2020, CRISPR was used to treat two severe cancer types, improving survival rates by 80% and 30%. The widespread adoption of gene editing technologies is driving innovation and growth in the market.

Investment and Regulatory Support

Investments in biotechnology, including CRISPR-Cas9 and other genome editing technologies, have boosted research & development in plant genomics. Both public and private sectors are investing heavily in these technologies, which drives innovation and market expansion. Additionally, many countries have established regulatory frameworks for genetically modified organisms (GMOs). These regulations provide clear guidelines for developing and commercializing genetically engineered crops, supporting market growth.

Challenges to Market Growth

Despite the advancements, strict and evolving regulatory frameworks for GMOs can create obstacles for their commercialization and adoption. Complying with complex, region-specific regulations can be expensive & time-consuming. Public concerns about the safety and long-term effects of GMOs on health and the environment can also limit market acceptance. Negative public sentiment and consumer reluctance to buy GMO products may impact market growth.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Competitive Landscape

The global market is highly competitive, with top biotechnology companies, pharmaceutical firms, and research institutions playing a dominant role. Key players like CRISPR Therapeutics AG, GenScript, and Lonza Group Ltd. are heavily investing in research & development to drive innovation and create advanced gene-editing technologies. Their growth strategies include expanding into new geographic markets and enhancing regional presence. Ensuring regulatory compliance & protecting intellectual property are critical to the responsible application of Genetic Engineering technologies.

For example, Thermo Fisher Scientific Launched a new suite of gene editing tools specifically designed for high-throughput applications. The company offers comprehensive CRISPR-Cas9 and TALEN gene editing toolkits designed to assist researchers in understanding how genomes influence phenotypes. The toolkits provide a full suite of solutions for every step in the gene-editing workflow, from designing CRISPR-Cas9 systems or TALEN constructs for precise genome modifications to efficient transfection into cells & validating genotypic and phenotypic outcomes.

Recent Market Developments

Intellia Therapeutics Unveils Groundbreaking Data on Redosing Potential of In Vivo CRISPR/Cas9 Therapy

• In June 2024, Intellia Therapeutics, Inc., a leading clinical-stage gene editing company pioneering CRISPR-based therapies, has unveiled groundbreaking data showing, for the first time, the potential for redosing with an investigational in vivo CRISPR/Cas9 genome editing therapy. The data, derived from the ongoing Phase 1 study of NTLA-2001—a single-dose therapy currently being developed for transthyretin (ATTR) amyloidosis—was presented at the Peripheral Nerve Society Annual Meeting, held from June 22–25 in Montreal, Canada.

Beam Therapeutics Reports Significant Progress in Hematology, Immuno-Oncology, and Genetic Disease Portfolios with Base Editing Advances

• In January 2023, Beam Therapeutics Inc., a biotechnology company developing precision genetic medicines through base editing, reported progress across the company’s hematology, immunology-oncology and genetic disease portfolios and provided updates on anticipated upcoming milestones.

Merck Licenses CRISPR-Cas9 Technology to Cellecta to Enhance Integration and Homology-Directed Repair Services

• In October 2023, Merck, a global leader in science and technology, announced that its Life Science division has entered into a licensing agreement with Cellecta, Inc., a functional genomics products and services company based in Mountain View, California. This agreement grants Cellecta access to Merck's patented CRISPR-Cas9 technology, enabling them to enhance their integration and homology-directed repair services.

The global Genetic Engineering market can be categorized as Product, Devices, Techniques, Application, End-User, and Region.